Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05348915 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
NCT05348915 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 242 participants.
The verdict
NCT05348915, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
Study Summary
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
Interventions
- DRUG Inclacumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2025-11-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05348915
The ClinicalTrials.gov registry entry for NCT05348915 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inclacumab is the first listed.
NCT05348915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05348915 about?
NCT05348915 is a clinical study titled "A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease". This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
What is the current status of trial NCT05348915?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2022-03-29. Estimated completion is 2025-11-07.
What interventions are being tested in trial NCT05348915?
The interventions under investigation include: Inclacumab (DRUG).
Who is sponsoring clinical trial NCT05348915?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.